Summary
Katacalcin (KC) is situated on the C-terminal side of the procalcitonin molecule and is cleaved like calcitonin (CT) from this precursor peptide. Serum levels of KC were measured in 22 patients with C-cell carcinoma with a specific and sensitive radioimmunoassay (normal range, <0.1–0.15 ng/ml). Basal serum KC values in C-cell carcinoma patients were 0.32-290 ng/ml. There was a good correlation between KC and CT (r=0.98,P<0.001). Serum KC, as well as CT, markedly increased after pentagastrin and calcium infusion. KC and CT were secreted in nearly equimolar amounts. During selective venous catheterization, KC and CT levels were increased in serum samples from veins draining tumor masses, which could be confirmed operatively. During the follow up, KC and CT measurements correlated well to the stage of disease. KC could be immunohistologically localized in C-cell carcinoma tissue. As a tumor marker, katacalcin is likely to be as useful as calcitonin in C-cell carcinoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- CEA:
-
carcinoembryonic Antigen
- CGRP:
-
Calcitonin-gene-related peptide
- CT:
-
Calcitonin
- KC:
-
Katacalcin
Literatur
Ali-Rachedi A, Varndell IM, Facer P, Hillyard CJ, Craig, RK, MacIntyre I, Polak JM (1983) Immunocytochemical localisation of katacalcin, a calcium lowering hormone cleaved from the human calcitonin precursor. J Clin Endocrinol Metab 57:680–682
Allison J, Hall L, MacIntyre I, Craig RK (1981) The contruction and partial characterization of plasmids containing complementary DNA sequences to human calcitonin precursor polyprotein. Biochem J 199:725–731
Craig RK, Hall L, Edbrooke MR, Allison J, MacIntyre I (1982) Partial nucloide sequence of human calcitonin precursor mRNA flanking cryptic peptides. Nature 295:345–347
Hillyard CJ, Myers C, Abeyasekera A, Stevenson JC, Craig RK, MacIntyre I (1983) Katacalcin: a new plasma calcium-lowering hormone. Lancet I:846–848
MacIntyre I, Hillyard CJ, Murphy PK, Reynolds JJ, Gaines Das RE, Craig RK (1982) A second calcium-lowering peptide from the human calcitonin precursor. Nature 300:460–462
MacIntyre I, Hillyard CJ, Reynolds JJ, Gaines Das RE, Craig RK (1984) A second plasma calcium-lowering peptide from the human calcitonin precursor — a re-evaluation. Nature 304:84
Raue F, Minne H, Streibl W, Ziegler R (1978) Calcitonin radioimmunoassay. Clinical application. In: Radioimmunoassay and Related Procedures in Medicin (International Atomic Energy Agency), Vol 2, pp 419–426
Raue F, Schmidt-Gayk H, Ziegler R (1983) Tumormarker beim C-Zell-Karzinom. Dtsch Med Wochenschr 108:283–287
Raue F, Boller G, Rix E, Schmidt-Gayk H, Ziegler R (1985) Secretion of calcitonin and carcinoembryonic antigen in long-term organ culture of human medullary thyroid carcinoma: biochemical and immunocytochemical studies. Klin Wochenschr 63:205–210
Roos BA, Huber MB, Birnbaum RS, Aron DC, Lindell AW, Lipps K, Baylin SB (1983) Medullary thyroid carcinoma secrete a non-calcitonin peptide corresponding to the carboxyl-terminal region of preprocalcitonin. J Clin Endocrinol Metab 56:802–807
Rougier P, Calmettes C, Laplanche L, Travagli JP, Lefevre M, Parmentier C, Milhand G, Tubiana M (1983) The value of calcitonin and carcinoembryonic antigen in the treatment and management of nonfamilial medullary thyroid carcinoma. Cancer 51:855–901
Stephanas AV, Samaan NA, Hill CS, Hickey RC (1979) Medullary thyroid carcinoma: Importance of serial serum calcitonin measurement. Cancer 43:825–837
Author information
Authors and Affiliations
Additional information
Mit Unterstützung der Deutschen Forschungsgemeinschaft (Ra 327/1-1) und Tumorzentrum Heidelberg/Mannheim
Ein Teil der Arbeit wurde auf der Jahrestagung Klinische Chemie Mannheim 1985, J. Clin. Chem. Clin. Biochem. 23 (1985) 618 Abstract B/38 vorgetragen
Rights and permissions
About this article
Cite this article
Raue, F., Boden, M., Girgis, S. et al. Katacalcin — Ein neuer Tumormarker beim C-Zell-Karzinom der Schilddrüse. Klin Wochenschr 65, 82–86 (1987). https://doi.org/10.1007/BF01745480
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01745480